Top

Published in:

01-02-2011 | Original Article

HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma

Authors: Kohei Otake, Keiichi Uchida, Kouji Tanaka, Yuhki Koike, Mikihiro Inoue, Kohei Matsushita, Motoko Ueeda, Kiyoshi Hashimoto, Takahito Kitajima, Yoshihiro Komada, Masato Kusunoki

Published in: Pediatric Surgery International | Issue 2/2011

Abstract

Purpose

We investigated the associations between hsMAD2 mRNA expression in tumor cells and sensitivity to paclitaxel or patient prognosis in neuroblastoma.

Methods

Fifty-one formalin-fixed paraffin-embedded tumor samples were manually microdissected to collect tumor cells, and RNA was purified. Nineteen clinical samples of advanced neuroblastoma showed appropriate quality of the isolated RNA for real-time reverse transcription-polymerase chain reaction (RT-PCR) analyses. The hsMAD2 expression levels were determined by real-time RT-PCR in 4 neuroblastoma cell lines and 19 clinical samples. The sensitivity to paclitaxel was assessed by WST-8 colorimetric assays and flow cytometry. HsMAD2 expression of the clinical samples was investigated for its association with prognosis in advanced neuroblastoma patients.

Results

There was a significant positive correlation between hsMAD2 mRNA expression and the sensitivity to paclitaxel in four neuroblastoma cell lines. High hsMAD2 expression may be correlated with paclitaxel-induced apoptosis. Kaplan–Meier survival curves were stratified by hsMAD2 expression using the median value as a cut-off point and analyzed for prognostic significance by the log-rank test (P = 0.0467). Furthermore, multivariate survival analysis revealed that only hsMAD2 expression had a significant impact on the overall survival rate.

Conclusions

Our results may warrant clinical application of paclitaxel in neuroblastoma treatment for poor prognosis patients.

Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369(9579):2106–2120. doi:10.1016/S0140-6736(07)60983-0 CrossRefPubMed

Berthold F, Hero B (2000) Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59(6):1261–1277CrossRefPubMed

Goldsmith KC, Hogarty MD (2005) Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 228(1–2):133–141. doi:10.1016/j.canlet.2005.01.048 CrossRefPubMed

Paffhausen T, Schwab M, Westermann F (2007) Targeted mycn expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett 250(1):17–24. doi:10.1016/j.canlet.2006.09.010 CrossRefPubMed

Li Y, Benezra R (1996) Identification of a human mitotic checkpoint gene: hsMAD2. Science 274(5285):246–248CrossRefPubMed

Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5(10):773–785. doi:10.1038/nrc1714 CrossRefPubMed

Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C (2004) Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430(7001):797–802. doi:10.1038/nature02820 CrossRefPubMed

Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325–2327CrossRefPubMed

Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R (2004) Response to paclitaxel, topotecan, and topotecan–cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol 22(20):4119–4126. doi:10.1200/JCO.2004.08.174 CrossRefPubMed

10.

Sudo T, Nitta M, Saya H, Ueno NT (2004) Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64(7):2502–2508CrossRefPubMed

11.

Tanaka K, Nishioka J, Kato K, Nakamura A, Mouri T, Miki C, Kusunoki M, Nobori T (2001) Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res 92(9):952–958PubMed

12.

Tanaka K, Mohri Y, Ohi M, Yokoe T, Koike Y, Morimoto Y, Miki C, Tonouchi H, Kusunoki M (2008) Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol) 20(8):639–646. doi:10.1016/j.clon.2008.06.010

13.

Biedler JL, Helson L, Spengler BA (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33(11):2643–2652PubMed

14.

Seeger RC, Rayner SA, Banerjee A, Chung H, Laug WE, Neustein HB, Benedict WF (1977) Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res 37(5):1364–1371PubMed

15.

Matsumura T, Sugimoto T, Sawada T, Amagai T, Negoro S, Kemshead JT (1987) Cell surface membrane antigen present on neuroblastoma cells but not fetal neuroblasts recognized by a monoclonal antibody (KP-NAC8). Cancer Res 47(11):2924–2930PubMed

16.

Sugimoto T, Horii Y, Hino T, Kemshead JT, Kuroda H, Sawada T, Morioka H, Imanishi J, Inoko H (1989) Differential susceptibility of HLA class II antigens induced by gamma-interferon in human neuroblastoma cell lines. Cancer Res 49(7):1824–1828PubMed

17.

Kisenge RR, Toyoda H, Kang J, Tanaka S, Yamamoto H, Azuma E, Komada Y (2003) Expression of short-form caspase 8 correlates with decreased sensitivity to Fas-mediated apoptosis in neuroblastoma cells. Cancer Sci 94(7):598–605CrossRefPubMed

18.

Toyoda H, Ido M, Hayashi T, Gabazza EC, Suzuki K, Kisenge RR, Kang J, Hori H, Komada Y (2004) Experimental treatment of human neuroblastoma using live-attenuated poliovirus. Int J Oncol 24(1):49–58PubMed

19.

Tanaka K, Otake K, Mohri Y, Ohi M, Yokoe T, Toiyama Y, Miki C, Tonouchi H, Kusunoki M (2009) Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer. Oncol Rep 21(6):1489–1494CrossRefPubMed

20.

Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK, Lichy JH (2001) Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem 47(2):195–201PubMed

21.

Ogawa M, Hori H, Ohta T, Onozato K, Miyahara M, Komada Y (2005) Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma. Clin Cancer Res 11(9):3485–3493. doi:10.1158/1078-0432.CCR-04-1781 CrossRefPubMed

22.

Surico G, Muggeo P, De Leonardis F, Rigillo N (2003) New paclitaxel–cisplatin based chemotherapy regimen for advanced stage, recurrent, or refractory neuroblastoma—preliminary report. Med Pediatr Oncol 40(2):130–132. doi:10.1002/mpo.10106 CrossRefPubMed

23.

Ramanathan RK, Rubin JT, Ohori NP, Belani CP (2000) Dramatic response of adult wilms tumor to paclitaxel and cisplatin. Med Pediatr Oncol 34(4):296–298. doi:10.1002/(SICI)1096-911X(200004)34:4<296:AID-MPO20>3.0.CO CrossRefPubMed

24.

Italiano A, Sirvent N, Michiels JF, Peyrade F, Otto J, Thyss A (2005) Tumour response to paclitaxel in an adult with relapsed nephroblastoma. Lancet Oncol 6(4):252–253. doi:10.1016/S1470-2045(05)70098-X CrossRefPubMed

25.

Li Z, Zhang J, Liu Z, Woo CW, Thiele CJ (2007) Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ 14(2):318–326. doi:10.1038/sj.cdd.4401983 CrossRefPubMed

26.

Jiang BH, Liu LZ (2008) Role of mtor in anticancer drug resistance: Perspectives for improved drug treatment. Drug Resist Updat 11(3):63–76. doi:10.1016/j.drup.2008.03.001 CrossRefPubMed

Title: HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma
Authors: Kohei Otake
Keiichi Uchida
Kouji Tanaka
Yuhki Koike
Mikihiro Inoue
Kohei Matsushita
Motoko Ueeda
Kiyoshi Hashimoto
Takahito Kitajima
Yoshihiro Komada
Masato Kusunoki
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Pediatric Surgery International / Issue 2/2011
Print ISSN: 0179-0358
Electronic ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-010-2780-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2011

Prenatal retinoic acid treatment upregulates late gestation lung protein 1 in the nitrofen-induced hypoplastic lung in late gestation

Protective mechanism of glutamine on the expression of proliferating cell nuclear antigen after cisplatin-induced intestinal mucosal injury

Nutritional supplementation with transforming growth factor-beta inhibits intestinal adaptation after massive small bowel resection in a rat

Src kinase family inhibitor PP2 induces aggregation and detachment of neuroblastoma cells and inhibits cell growth in a PI3 kinase/Akt pathway-independent manner

Late administration of antenatal vitamin A promotes pulmonary structural maturation and improves ventilation in the lamb model of congenital diaphragmatic hernia

Downregulation of Midkine gene expression and its response to retinoic acid treatment in the nitrofen-induced hypoplastic lung